The U.S. Food and Drug Administration (FDA) announced on Thursday that Ranbaxy Laboratories (PINK:RBXZF) had halted production of its generic version of Lipitor, a cholesterol drug, while it reviews operations to determine how glass particles contaminated some shipments of the medication.
No shortage in the supply of the drug — marketed as atorvastatin — was expected due to Ranbaxy’s production stoppage, the Wall Street Journal noted.
Discovery of glass particles in some bottles of atorvastatin prompted the company, which is the India-based subsidiary of Japan’s Daiichi Sankyo PINK:DSNKY), to recall a large number of shipments on November 89. That followed an August recall of 32,000 bottles of atorvastatin produced by Ranbaxy after a 20mg atorvastatin was found in a bottle marked for 10mg dosages of the drug.
So far, the FDA indicated that it had received reports of any injuries due to the glass particles.